TITLE
Antonia Kolokythas: Management of benign odontogenic tumors
TALK INFO
Join Dr. Kolokythas for an insightful presentation on the management of benign odontogenic lesions. Excluding hamartomas (odontomas), keratocystic odontogenic tumors (KOTs), and ameloblastomas stand out as the most prevalent among these conditions. Their locally infiltrative behavior poses challenges, contributing to high recurrence rates despite traditional treatment methods like simple enucleation or excision proving inadequate. Left untreated, these lesions can lead to significant disfigurement and functional impairment. Understanding the latest best practices and potential future therapies is crucial for achieving effective disease management. Don't miss this opportunity to enhance your knowledge and clinical approach to these complex conditions. Join us for an engaging discussion.
THIS EVENT IS ACCREDITED
CLINICAL PATHWAY
Pathology
SPEAKER
DATE
04/11/24
LEARNING OBJECTIVES
By the end of this session, participants will be able to:
Understand the epidemiology, clinical features, and behavior of keratocystic odontogenic tumors (KOTs) and ameloblastomas.
Recognize the challenges in managing these lesions, including their locally infiltrative nature and high recurrence rates.
Describe current treatment strategies and their limitations in preventing recurrence and functional or aesthetic impairment.
Explore emerging therapies and evidence-based approaches for effective management of benign odontogenic lesions.
Apply updated knowledge to optimize clinical decision-making and patient outcomes in cases of complex odontogenic lesions.
ABOUT THE SPEAKER
Born and raised in Greece, Dr. Antonia Kolokythas completed her residency in Oral and Maxillofacial surgery at the University of Illinois at Chicago. She also completed a Head and Neck and Reconstruction Fellowship at the University of Maryland and then an additional Fellowship with emphasis on Head and Neck oncology research at the University of California San Francisco. She is a full time academic surgeon and Residency Program Director and was Dept Chair and Residency Program Director University of Rochester. Her clinical practice and research focuses on oral cancer early diagnosis and treatment. She is a Fellow of the American College of Surgeons since 2015.
CE ACCREDITATION
surgeOn is an ADA CERP Recognized Provider. ADA CERP is a service of the American Dental Association to assist dental professionals in identifying quality providers of continuing dental education. ADA CERP does not approve or endorse individual courses or instructors, nor does it imply acceptance of credit hours by boards of dentistry. surgeOn designates this activity for 1 credit hour of continuing education credits.
This event may also be accredited by the European Accreditation Council for Continuing Medical Education (EACCME®) for a maximum of 1 European CME credits (ECMEC®s). Each medical specialist should claim only those hours of credit that he/she actually spent in the educational activity. If you are a learner based in the U.S. or Canada EACCME credits are recognized by the American Medical Association (AMA) and the Royal College of Physicians and Surgeons of Canada.
DECLARATION
In accordance with criterion 13 of document UEMS 2023.07.rev “EACCME® Criteria for the Accreditation of Live Educational Events (LEEs)” and the Standard v. Commercial or Promotional Conflict of Interest, published by the American Dental Association Continuing Education Recognition Program (ADA CERP), all surgeON presenters sign a Conflict of Interest form to document all perceived or actual conflicts of interest for the last 3 years, whether due to a financial or other relationship. This document can be viewed at the beginning of the event or on request by emailing info@surgeon-events.org No fee, honorarium or arrangement for re-imbursement of expenses in relation to the this event has been provided to the speaker.
